NVAX — Novavax, Inc.

NVAX Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $1.1 billion for the full year 2025, a 65% increase year-over-year; Q4 revenue was $147 million, up 67% from Q4 2024.
• Non-GAAP Adjusted Revenue: $1.1 billion, exceeding guidance by approximately $50 million.
• Positive Income: Reported for both the full year and Q4 2025.
• Cash Position: Ended 2025 with $857 million in cash and receivables; additional $80 million secured in Q1 2026 from new agreements.
• Cost Reductions: Combined R&D and SG&A expenses decreased by 42% in Q4 and 53% for the full year 2025.

2. Strategic Updates and Business Highlights

• Partnerships: New agreement with Pfizer for Matrix-M with potential for significant revenue through milestones and royalties. Continued success with existing partnerships, including Sanofi and Takeda.
• R&D Focus: Advancements in the pipeline, including C. diff, shingles, and RSV vaccines. Emphasis on leveraging Matrix technology for new adjuvants and expanding its application beyond infectious diseases.
• Operational Efficiency: Transitioned to a leaner operating model, reducing expenses while maintaining R&D capabilities.

3. Forward Guidance and Outlook

• 2026 Revenue Framework: Expected adjusted total revenue between $230 million and $270 million, with significant contributions anticipated from Nuvaxovid and partnerships.
• Cost Guidance: Targeting combined R&D and SG&A expenses of $325 million in 2026, with a further reduction to $225 million in 2027.
• Long-Term Goals: Aiming for non-GAAP profitability by 2028, contingent on successful product development and commercialization efforts.

4. Bad News, Challenges, or Points of Concern

• Regulatory Environment: Ongoing uncertainties in the macro and regulatory landscape for vaccine companies, particularly in the U.S.
• Dependence on Partnerships: Future revenue heavily reliant on the success of partners like Sanofi in commercializing Nuvaxovid and other products.
• Market Competition: Facing competitive pressures from other vaccine manufacturers, particularly in the COVID vaccine space.

5. Notable Q&A Insights

• Sanofi Partnership: Executives expressed confidence in the partnership with Sanofi, despite leadership changes, emphasizing a strong collaborative relationship.
• Pipeline Prioritization: The company is exploring multiple early-stage programs, with no specific prioritization disclosed but an intent to advance one or more into clinical trials as early as 2027.
• Matrix Technology Interest: High interest from various pharmaceutical companies in Matrix-M, with several MTAs signed and ongoing discussions for potential partnerships.
• Long COVID Data: R&D highlighted epidemiological data suggesting vaccinated individuals have a lower risk of developing long COVID compared to unvaccinated individuals.
• Commercialization Strategy: Novavax is focusing on partnerships rather than building a commercial framework, with openness to co-promote if a significant product emerges.

This summary encapsulates the key points from the earnings call, highlighting financial performance, strategic initiatives, outlook, challenges, and insights from the Q&A session.